New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target.

Understanding how the immune system responds to the respiratory virus HMPV is crucial for developing vaccines and anti-viral treatments.

Virus-like particles containing a protein from human metapneumovirus are a promising vaccine candidate for this respiratory virus.

Understanding how chikungunya virus binds to and enters cells offers a new target for antiviral medications.

The structural architecture of the reovirus attachment protein is required for efficient reovirus infection of host cells.

The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.